Advanced Viral Research Corp., of Yonkers, N.Y., received two notices of allowance for patents related to alleviating side effects in patients undergoing treatments for cancer, including a method for reducing the side effects in patients undergoing chemotherapy.
Chemokine Therapeutics Corp., of Vancouver, British Columbia, was granted U.S. Patent No. 7,354,899, titled "Methods of treating Autoimmune Diseases Comprising Administering CXCR4 Antagonists," which relates to the treatment of diseases such as multiple sclerosis, arthritis and psoriasis, and Patent No. 7,368,425, titled "Cyclic Peptides for Modulating Growth of Neo-Vessels and Their Use in Therapeutic Angiogenesis," which is related to the use of chemokine SDF-1 to induce blood vessel growth in cardiovascular and vascular diseases. The company also received U.S. Patent No. 7,378,098, titled "CXC Chemokine Receptor 4 Agonist Peptides," which relates to the treatment of patients in need of bone marrow or stem cell transplantation.
Collegium Pharmaceutical Inc., of Cumberland, R.I., received U.S. Patent No. 7,399,488, which relates to its tamper-resistant, abuse-deterrent formulation platform. It covers orally administratable compositions comprising the company's micro-particle formulations and will protect the DETERx technology.
Cytori Therapeutics Inc., of San Diego, received U.S. Patent No. 7,390, 484, relating to the Celution System. The patent protects the company's rights to manufacture the Celution System in the U.S. for commercialization in all markets, including Europe and Asia-Pacific.
EntreMed Inc., of Rockville, Md., received U.S. Patent No. 7,371,741, covering analogues of 2-methoxyestradiol. It grants the company composition-of-matter and method of use protection for 2ME2 analogues in oncology and a range of nononcology indications, such as inflammatory and immune disorders, rheumatoid arthritis and other diseases characterized by abnormal cell division.
Eurand NV, of Dayton, Ohio, received U.S. Patent No. 7,387,793, titled "Modified Release Dosage Forms of Skeletal Muscle Relaxants," which includes claims covering Amrix (cyclobenzaprine hydrochloride), which is marketed in the U.S. by Frazer, Pa.-based Cephalon Inc.
Intradigm Corp., of Palo Alto, Calif., received a notice of allowance for a patent claiming methods of enhancing the RNA silencing activity of an RNAi agent in a mammalian or plant cell.
Lipid Sciences Inc., of Pleasanton, Calif., received U.S. Patent No. 7,375,191, which extends the company's ownership over therapeutic HDL compositions provided by its extracorporeal delipidation process. The company also received U.S. Patent No. 7,393,826, which also relates to the HDL therapy platform and, in particular, to the selective delipidation process.